By Pooja Toshniwal Paharia A six-year analysis from a major Bronx health system reveals how the pandemic reshaped asthma ...

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

Proton pump inhibitor (PPI) use in patients with chronic obstructive airway diseases is associated with an increased exacerbation risk.

A recent study explored exacerbation history to determine what it revealed about prognosis. The findings suggested that exacerbation severity history was predictive of future exacerbation status.

Glucagon-like peptide-1 receptor agonists (GLP-1) is linked to a significant reduction in asthma exacerbations for overweight, obese and morbidly obese patients without diabetes, according to new ...

Investigators of a 3-year observational study identified independent risk factors for exacerbations related to chronic obstructive pulmonary disease (COPD) and successfully developed a novel risk ...

In an observational study that began enrollment last month, researchers will determine if continuous, remote lung sound ...

Please provide your email address to receive an email when new articles are posted on . Exacerbation risk factors in this population included GERD, chronic bronchitis, high symptom burden and ...

Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...

This page lists all known medications that could potentially lead to 'Exacerbation of asthma' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Acute exacerbations adversely affect patients with chronic obstructive pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of inflammatory airway diseases. We performed a ...

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic ...